Snus: The Swedish Miracle That the Rest of the World Ignored

Sweden is about to become the first country to achieve a smoking rate below 5%—the threshold the WHO defines as 'smoke-free.' Swedish men smoke at less than half the European average. Swedish lung cancer mortality is the lowest in the developed world. The Swedish cancer registry shows diverging curves for oral and lung cancers that are the inverse of every other country that experienced a 20th-century smoking epidemic. The variable that explains this epidemiological miracle is not better cessation services, stricter advertising bans, or more aggressive taxation. It's snus—a moist oral tobacco product placed under the upper lip that Swedish men have been using for over 200 years. The rest of the world has spent decades ignoring the Swedish experience. The question is why.

Snus is not harmless, and no credible proponent claims it is. It contains tobacco-specific nitrosamines (TSNAs), albeit at dramatically lower levels than American-style oral tobacco products because of differences in the curing process (Swedish snus is pasteurized, not fire-cured). It increases the risk of pancreatic cancer, though the absolute risk is small. It may contribute to cardiovascular disease, though the epidemiological signal is weaker than for smoking. It causes localized oral lesions at the site of placement. It's addictive. What snus does NOT do, with overwhelming epidemiological certainty, is cause lung cancer, COPD, or any other respiratory disease—because there is no combustion, no inhalation, no smoke. For the roughly one million Swedish men who use snus daily instead of smoking cigarettes, the health calculus is unambiguous: they are far better off than if they smoked.

The population-level data from Sweden is the strongest real-world evidence for the harm reduction potential of non-combustible nicotine products. Swedish men have not stopped using nicotine. What they've done is switch from a high-risk delivery system (cigarettes) to a lower-risk one (snus). The transition was not orchestrated by public health authorities—in fact, the Swedish government fought it for decades, maintaining higher taxes on snus than cigarettes for much of the 20th century and only recently acknowledging the public health benefit. The transition was driven by consumers, who preferred snus for cultural and practical reasons, and by market forces that made snus widely available and socially acceptable in a way that smoking eventually ceased to be. Public health followed the evidence, reluctantly, decades after the evidence was clear.

The rest of the world's failure to learn from Sweden is a case study in how precautionary-principle absolutism and institutional inertia can override epidemiological evidence. Snus is banned in every EU country except Sweden (which negotiated an exemption when it joined the union). Australia, New Zealand, and many other countries prohibit the sale of oral tobacco products entirely. The WHO FCTC's official position is that all tobacco products are harmful and that the appropriate policy response is to discourage all use. The logic is that acknowledging snus as lower-risk would 'normalize' tobacco use and potentially serve as a gateway to smoking—even though the Swedish evidence shows exactly the opposite: snus use has served as an off-ramp FROM smoking, not an on-ramp TO smoking. The gateway hypothesis, which has been tested extensively in Sweden and found wanting, continues to drive policy in countries that have never allowed snus to compete with cigarettes.

The industry dimension complicates the story. Swedish Match, the dominant snus manufacturer, is a tobacco company. It has lobbied for snus legalization in the EU and elsewhere, and its interests are commercial, not philanthropic. Public health advocates who oppose snus often point to the company's profit motive as evidence that harm-reduction claims are industry propaganda—a charge that is simultaneously true (the company does profit) and irrelevant (the epidemiological data is what it is, regardless of who profits from it). The deeper concern is that relaxing restrictions on oral tobacco would open the door for Big Tobacco to market a new generation of products—nicotine pouches, flavored snus, 'modern oral nicotine'—using the Swedish experience as a fig leaf while targeting youth and never-users. This is a legitimate concern, but it's an argument for smart regulation, not for maintaining a ban whose primary effect is to protect the cigarette market from lower-risk competition.

The emerging market for nicotine pouches—tobacco-free products that deliver nicotine in a snus-like format—may finally break the policy logjam. Because pouches contain no tobacco leaf, they circumvent the statutory bans on oral tobacco that exist in many countries, and they don't trigger the FCTC's tobacco-product provisions in the same way. This regulatory novelty has created a natural experiment: as nicotine pouches proliferate in countries where snus is banned, the question of whether non-combustible nicotine products reduce smoking prevalence will be answered not by Sweden's unique cultural context but by the behavior of consumers in dozens of countries with different cultures, regulatory frameworks, and smoking patterns. If pouch uptake is associated with accelerated smoking declines, the Swedish model will be replicated inadvertently. If pouch uptake creates a parallel epidemic of nicotine use without reducing smoking, the precautionary principle will be vindicated. The experiment is running. The results will arrive over the next decade.

The Swedish snus experience offers a lesson that extends beyond nicotine: when a population has access to a less harmful way to meet a demand that isn't going away, health improves. This isn't ideological—it's observational epidemiology, replicated across decades and cohorts, stubbornly consistent. The counterarguments—that snus might be a gateway, that acknowledging it as lower-risk might 'send the wrong message,' that the ideal outcome is total nicotine abstinence—are refuted by the mortality curves. Sweden's public health establishment has gradually, grudgingly accepted this. The rest of the world, with far more to gain from reducing smoking-related mortality, remains largely in denial. As one Swedish epidemiologist told a 2024 conference: 'We're not asking the world to adopt snus. We're asking the world to look at our data and explain why our cancer rates are so low. If you can't explain it without acknowledging snus, you might want to reconsider your position.'